Figure 2.
Differences in adverse event frequencies: combination therapies versus vemurafenib monotherapy. CPK, creatine phosphokinase; cSCC, cutaneous squamous cell carcinoma; PPH, palmoplantar hyperkeratosis.
Differences in adverse event frequencies: combination therapies versus vemurafenib monotherapy. CPK, creatine phosphokinase; cSCC, cutaneous squamous cell carcinoma; PPH, palmoplantar hyperkeratosis.